Back
17 June 2025
The ITA reports that the player Omid Hadiazhar has agreed¹ to the consequences imposed for his anti-doping rule violation (ADRV).
The player provided a sample on 18 January 2024 during an in-competition anti-doping control at the 2024 IWBF Asia Oceania Championships held in Bangkok, Thailand. After analysis by a World Anti-Doping Agency (WADA)-accredited laboratory, the sample returned an adverse analytical finding² for tramadol.
Tramadol is prohibited under the WADA Prohibited List in the category of S7. Narcotics. It is prohibited in-competition and is classified as a specified substance. Tramadol is an opioid used to relieve and treat moderate to severe pain.
The player did not challenge his ADRV and agreed with the consequences proposed by the ITA, namely a period of ineligibility of two years from 25 March 2024 until 24 March 2026 and the disqualification of his individual competitive results from 18 January 2024 onwards.
The relevant stakeholders, namely the World Anti-Doping Agency and the Iran National Anti-Doping Organization, have a right to appeal the consequences imposed before the appeals division of the Court of Arbitration for Sport.
¹ Players have the right to choose not to have their case referred to a hearing panel. In these instances, the anti-doping organisation will assess the player’s case file and establish the applicable consequences pursuant to the anti-doping rules and the player will have the right to accept the proposed consequences. If the player refuses the proposed consequences, the case is transferred to a hearing panel. This resolution mechanism is provided for in articles 8.3.1 and 8.3.3 of the IWBF anti-doping rules and 8.3 of the World Anti-Doping Code and is commonly referred to as an agreement on consequences and is deemed an IWBF/ITA decision. The player’s National Anti-Doping Organisation and the World Anti-Doping Agency have the right to appeal the agreement on consequences before the competent appeal body.
² A report from a WADA-accredited laboratory that, consistent with the International Standard for Laboratories, establishes in a sample the presence of a prohibited substance or its metabolites or markers or evidence of the use of a prohibited method.
